A new clinical trial underway in the Lowcountry is drawing attention for its unconventional — and potentially groundbreaking ...

In a review of previous studies, McMaster University researchers observe a stronger signal for psilocybin as a treatment for obsessive-compulsive disorder than cannabinoids.

New studies show that psychedelics could unlock safer treatments for chronic pain, mood disorders, and even neuroprotection.

By increasing neuroplasticity, psychedelics may both enhance creativity and be useful for treating a variety of psychiatric ...

U.S. Sen. Dave McCormick is at odds with President Donald Trump’s move to reclassify marijuana as a less dangerous drug, ...

President Trump signed an executive order on Thursday to expedite the reclassification of marijuana from a Schedule I drug to Schedule III, potentially opening doors for expanded medical research.

President Donald Trump signed an executive order Thursday that could reclassify marijuana as a less dangerous drug and open ...

Cannabis: dangerous, or dangerously misunderstood? President Trump’s executive order to downgrade marijuana from a schedule one to a schedule three drug ...

President Donald Trump on Thursday ordered federal agencies to quickly ease restrictions on marijuana and make CBD more ...

Reclassification to a Schedule III drug and possible Medicare coverage for pot could unlock new investment from ...

Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...

President Trump signed an executive order on Thursday that launches a pilot program authorizing Medicare to cover cannabis ...